Invitrogen, BioTek Collaborate on Tech Validation Program
Invitrogen and BioTek Instruments are collaborating to validate the compatibility of their technologies, and they plan to continue to develop and promote joint applications for the drug discovery market, the microplate and software maker BioTek said this week.
Under the collaboration, the companies have validated the compatibility of Invitrogen’s reagents and other technologies with BioTek’s microplate detection tools. So far, the companies have validated five Invitrogen drug discovery products with BioTex’s 4 Multi-Mode Microplate Reader including: the GeneBlazer; LanthaScreen, Adapta Universal Kinase Assay; the Z-Lyte; and the Omnia.
Invitrogen also has certified BioTek’s Synergy 2 Multi-Mode Microplate Readers for use with its LanthaScreen kinase and nuclear hormone receptor technology.
“Through this partnership, drug discovery researchers will be able to obtain integrated instrumentation and reagent solutions, thereby removing the frustration of discovering that the biological assay system they have chosen is not compatible with the instrumentation,” John Printen, director of Invitrogen’s cell signaling business segment, said in a statement.
In an e-mail this week to CBA News, BioTek said that it has collaborations with other reagent vendors, including Cisbio and Promega. Although it is difficult to measure a specific collaboration’s impact on revenue, “having collaborations in place with reagent vendors probably helps in 20 percent to 30 percent of cases,” the company said.
Stem Cell Sciences In-Licenses Prolume GFP Technology
Stem Cell Sciences this week announced that it had licensed certain rights to green fluorescent protein technology from Prolume. SCS will incorporate the GFP technology, which acts as a gene expression marker, into its SC Proven research reagents portfolio as well as in certain stem cell technologies used in services assays for high-throughput drug screening and toxicity testing.
“Prolume GFPs have the highest absorption,” Bruce Bryan, Prolume president and CEO, told CBA News in an e-mail this week. He also said that they have 98 percent quantum efficiency.
Galapagos Reaches Two Milestones, Lands $1.2M Payment From GlaxoSmithKline
Galapagos announced this week that it has reached two new milestones in its multi-year drug discovery alliance in osteoarthritis with GlaxoSmithKline, triggering a payment of €800,000 ($1.2 million) from GSK.
The announcement marks the fifth milestone payment made to Galapagos since the start of the osteoarthritis alliance. To date, Galapagos has received a total of €15.9 million in access fees and milestone payments from GSK under the alliance.
Rentschler Opens 2,500 L GMP Suite
Rentschler Biotechnologie has started operating a 2,500 L multi-process production suite at its facility in Laupheim, Germany, the company announced this week. Rentschler Biotechnologie now has nine stand-alone Good Manufacturing Practices suites with volumes of 30, 250, 500, and 2,500 liters, enabling the production of material for clinical trials and for market supply.
The 2,500 L bioreactor is designed such that batch, fed-batch, or perfusion cell culture processes can be run. Protein purification is performed in two suites for pre- and post-virus inactivation, respectively.